Protagenic Therapeutics, Inc.
PTIX
$0.92
-$0.11-10.32%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 851.30K | -37.60K | 771.30K | 840.60K | 814.30K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 961.20K | 120.30K | 925.10K | 1.11M | 1.21M |
| Operating Income | -961.20K | -120.30K | -925.10K | -1.11M | -1.21M |
| Income Before Tax | -963.60K | 5.08M | 2.21M | -869.50K | -5.06M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -963.60K | 5.08M | 2.21M | -869.50K | -5.06M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -963.60K | 5.08M | 2.21M | -869.50K | -5.06M |
| EBIT | -961.20K | -120.30K | -925.10K | -1.11M | -1.21M |
| EBITDA | -952.90K | -108.80K | -912.50K | -1.10M | -1.20M |
| EPS Basic | -0.53 | 2.69 | 1.14 | -0.47 | -1.37 |
| Normalized Basic EPS | -0.33 | -0.37 | 0.71 | -0.29 | -0.66 |
| EPS Diluted | -0.53 | 2.69 | 1.14 | -0.47 | -1.37 |
| Normalized Diluted EPS | -0.33 | -0.37 | 0.71 | -0.29 | -0.66 |
| Average Basic Shares Outstanding | 1.81M | 1.89M | 1.93M | 1.85M | 3.70M |
| Average Diluted Shares Outstanding | 1.81M | 1.89M | 1.93M | 1.85M | 3.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |